Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities

MedChemComm
2019.0

Abstract

Previously, we designed and synthesized a series of bis-substituted aromatic amide-based histone deacetylase (HDAC) inhibitors. In this study, we report the replacement of a bromine atom by different amides on the phenyl ring of the CAP region. Representative compounds 9d and 10k exhibited low nanomolar IC50 values against HDAC1, which were ten times lower than that of the positive control SAHA. The IC50 of 9d against the human A549 cancer cell line was 2.13 μM. Furthermore, 9d increased the acetylation of histones H3 and H4 in a dose-dependent manner. Moreover, 9d significantly arrested A549 cells at the G2/M phase and induced A549 cell apoptosis. Finally, molecular docking investigation rationalized the high potency of compound 9d.

DOI： 10.1039/C9MD00306A

Knowledge Graph

Similar Paper

Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities
MedChemComm 2019.0
Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities
Bioorganic & Medicinal Chemistry Letters 2019.0
Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors
Bioorganic & Medicinal Chemistry 2015.0
2-Aroylindoles and 2-Aroylbenzofurans with N-Hydroxyacrylamide Substructures as a Novel Series of Rationally Designed Histone Deacetylase Inhibitors
Journal of Medicinal Chemistry 2007.0
Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR
European Journal of Medicinal Chemistry 2009.0
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
European Journal of Medicinal Chemistry 2009.0
Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors
Bioorganic & Medicinal Chemistry 2022.0
Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group
ACS Medicinal Chemistry Letters 2013.0
Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry 2016.0
N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: Design, synthesis, SAR studies, and in vivo antitumor activity
Bioorganic & Medicinal Chemistry Letters 2009.0